

Product Analysis Certificate

Control Lentiviral CRISPR sgRNA Construct
sg_CopGFP_D1 Control in pRSG17-U6-sg-UbiC-TagGFP2-2A-Puro (plasmid)
Reorder# SGCTL-COP-pRSG17



Control Lentiviral CRISPR sgRNA Construct

Shipment Contents: Control Lentiviral CRISPR sgRNA Construct (Plasmid)
sg_CopGFP_D1 Control in pRSG17-U6-sg-UbiC-TagGFP2-2A-Puro (plasmid)
— Store at -20°C

Description:

Cellecta's two-vector CRISPR/Cas9 system can be used for knocking out gene expression *in vivo* or *in vitro* by using a combination of an sgRNA (single guide RNA) expression vector along with a Cas9 nuclease expression vector. Permanent 100% knockout can be achieved in virtually any cell line by using Cellecta's lentiviral-based CRISPR constructs. Expression of both the sgRNA and Cas9 is stable, and the system can be used in dividing or non-dividing cells or whole model organisms.

Cas9-only Expression Vectors are available separately from Cellecta:

- pRCCB-CMV-Cas9-2A-Blast, Cat.#s SVC9B-PS (plasmid, 25 µg), SVC9B-VS (packaged, 1×10^6 TU)
- pRCCH-CMV-Cas9-2A-Hygro, Cat.#s SVC9-PS (plasmid, 25 µg), SVC9-VS (packaged, 1×10^6 TU)

The Control Lentiviral CopGFP sgRNA Construct expresses an sgRNA that targets a variant of destabilized CopGFP. It does not target any known human, mouse, or rat genes.

The plasmid sgRNA construct can be packaged into VSV-G pseudotyped viral particles using most commercially-available second or third-generation packaging mixes or Cellecta's second-generation psPAX2/pMD2.G packaging plasmid mix:

Cat.# CPCP-K2A, Ready-to-use Lentiviral Packaging Plasmid Mix, 250 µg (for 25 x 10-cm plates)

The titer of packaged constructs can be functionally determined by transduction of 293T cells and either FACS of RFP- or GFP-positive cells, antibiotic selection assay, or by PCR titering of integrated viral DNA.

Biosafety Level: BSL-2

Storage: -20°C

Shelf Life: 2 years from date of receipt

Shipping Conditions: Room Temperature, Blue Ice, or Dry Ice

Product Information (Cellecta Website):

User Manual: <https://www.cellecta.com/product-manuals-and-certificates/>
Vector Info (Sequence, etc.): <https://www.cellecta.com/vector-information/>

Product Analysis Certificate

Control Lentiviral CRISPR sgRNA Construct
sg_CopGFP_D1 Control in pRSG17-U6-sg-UbiC-TagGFP2-2A-Puro (plasmid)
Reorder# SGCTL-COP-pRSG17



Contents:

Catalog #	Description
SGCTL-COP-pRSG17	Control Lentiviral CRISPR sgRNA Expression Construct sg_CopGFP_D1 Control in pRSG17-U6-sg-UbiC-TagGFP2-2A-Puro (plasmid) Gene ID: n/a Reorder#: SGCTL-COP-pRSG17 25 µg, 0.5 µg/µl (50 µl × 1 tube) Lot# 17102513; Store at -20°C
Target Sequence:	AAGATCGAGTGCCGCATCAC
Insert Sequence + tracrRNA:	<u>ACCGAAGATCGAGTGCCGCATCAC</u> GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCT AGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTCG
Sequencing QC:	NNNNNNNTCNTGNGTAGTTTGCAGTTTTAAAAATTATGTTTTAAAAATGGACTATCATATGCTTACCGTAAC TTGAAAGTATTTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAAGATCGAGTGCCG CATCACGTTTAAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGA AAAAGTGGCACCGAGTCGGTGCTTTTTTCGGACTGTAGAACTCTGAACCTCGAGCAATTTAAAAGAAAAG GGGGATTGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
Sequencing Primer:	ATTAGTACAAAATACGTGACGTAGAA (U6-3)

Design of Collecta sgRNA Constructs:

ACCG-sgRNA-tracrRNA-TTCG

Product Analysis Certificate

Control Lentiviral CRISPR sgRNA Construct
sg_CopGFP_D1 Control in pRSG17-U6-sg-UbiC-TagGFP2-2A-Puro (plasmid)
Reorder# SGCTL-COP-pRSG17



Terms and Conditions

Cellecta, Inc. Limited License

Cellecta grants the end user (the "Recipient") of the Control CRISPR sgRNA Construct (the "Product") a non-transferable, non-exclusive license to use the reagents for internal research use only as described in the enclosed protocols; in particular, research use only excludes and without limitation, resale, repackaging, or use for the making or selling of any commercial product or service without the written approval of Cellecta, Inc. -- separate licenses are available for non-research use or applications. The Product is not to be used for human diagnostics or included/used in any drug intended for human use. Care and attention should be exercised in handling the Product by following appropriate research laboratory practices.

Cellecta's liability is expressly limited to replacement of Product or a refund limited to the actual purchase price. Cellecta's liability does not extend to any damages arising from use or improper use of the Product, or losses associated with the use of additional materials or reagents. This limited warranty is the sole and exclusive warranty. Cellecta does not provide any other warranties of any kind, expressed or implied, including the merchantability or fitness of the Product for a particular purpose. Use of the Product for any use other than described expressly herein may be covered by patents or subject to rights other than those mentioned. Cellecta disclaims any and all responsibility for injury or damage that may be caused by the failure of the Recipient or any other person to use the Product in accordance with the terms and conditions outlined herein.

The Recipient may refuse these licenses by returning the enclosed Product unused. By keeping or using the enclosed Product, you agree to be bound by the terms of these licenses. The laws of the State of California shall govern the interpretation and enforcement of the terms of these Licenses.

Limited Use Licenses

The Recipient acknowledges that Product has been developed by Cellecta based on licenses from Third Parties and agrees with the Terms of Limited Use for the Recipient provided by the Third Parties:

Life Technologies Corporation End-User Label License for the use of Lentiviral Expression System:

"This product or service (based upon the Lentiviral Expression System) is sublicensed from Life Technologies Corporation under U.S. Patent Nos. 5,686,279; 5,834,256; 5,858,740; 5,994,136; 6,013,516; 6,051,427; 6,165,782; 6,218,187; 6,428,953; 6,924,144; 7,083,981 and 7,250,299 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for nonhuman research use requires a license from GBP IP, LLC. Please contact GBP IP, LLC 537 Steamboat Road, Suite 200, Greenwich, CT 06830. Use of this technology to make or sell products or offer services for consideration in the research market requires a license from Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008."

Evrogen IP JSC End-User Label License for the use of lentiviral shRNA constructs comprising TagRFP-encoded gene:

"This product is for internal non-commercial research use only. No rights are conveyed to modify or clone the gene encoding fluorescent protein contained in this product. The right to use this product specifically excludes the right to validate or screen compounds. For information on commercial licensing, contact Evrogen Licensing Department, email: license@evrogen.com".

Terms and Conditions are also available online at <https://www.cellecta.com/company/legal-information/terms-and-conditions/>.

© 2018 Cellecta, Inc. All Rights Reserved.

Trademarks

CELLECTA is a registered trademark of Cellecta, Inc.